Monopar Therapeutics Inc (NASDAQ:MNPR) has a beta value of 1.15 and has seen 57497.0 shares traded in the last trading session. The company, currently valued at $262.91M, closed the last trade at $43.10 per share which meant it lost -$1.58 on the day or -3.54% during that session. The MNPR stock price is -25.99% off its 52-week high price of $54.30 and 96.17% above the 52-week low of $1.65. If we look at the company’s 10-day average daily trading volume, we find that it stood at 71310.0 shares traded. The 3-month trading volume is 80.47K shares.
The consensus among analysts is that Monopar Therapeutics Inc (MNPR) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
Monopar Therapeutics Inc (NASDAQ:MNPR) trade information
Sporting -3.54% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the MNPR stock price touched $43.10 or saw a rise of 20.63%. Year-to-date, Monopar Therapeutics Inc shares have moved 95.91%, while the 5-day performance has seen it change -11.06%. Over the past 30 days, the shares of Monopar Therapeutics Inc (NASDAQ:MNPR) have changed 60.16%. Short interest in the company has seen 30636.0 shares shorted with days to cover at 0.49.
Wall Street analysts have a consensus price target for the stock at $29.5, which means that the shares’ value could drop -46.1% from current levels. The projected low price target is $22.0 while the price target rests at a high of $37.0. In that case, then, we find that the current price level is 14.15% off the targeted high while a plunge would see the stock lose 48.96% from current levels.
Monopar Therapeutics Inc (MNPR) estimates and forecasts
The company’s shares have gained 1790.35% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -14.80% over the past 5 years. Earnings growth for 2025 is a modest 57.77% while over the next 5 years, the company’s earnings are expected to increase by 21.48%.
MNPR Dividends
Monopar Therapeutics Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Monopar Therapeutics Inc (NASDAQ:MNPR)’s Major holders
Insiders own 37.01% of the company shares, while shares held by institutions stand at 45.53% with a share float percentage of 72.28%. Investors are also buoyed by the number of investors in a company, with Monopar Therapeutics Inc having a total of 20.0 institutions that hold shares in the company. The top two institutional holders are MILLENNIUM MANAGEMENT LLC with over 0.19 million shares worth more than $0.15 million. As of 2024-06-30, MILLENNIUM MANAGEMENT LLC held 1.2159% of shares outstanding.
The other major institutional holder is GEODE CAPITAL MANAGEMENT, LLC, with the holding of over 60036.0 shares as of 2024-06-30. The firm’s total holdings are worth over $44906.0 and represent 0.3757% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund. As of Sep 30, 2024 , the former fund manager holds about 0.15% shares in the company for having 9.03 shares of worth $0.39 million while later fund manager owns 9.39 shares of worth $0.4 million as of Nov 30, 2024 , which makes it owner of about 0.15% of company’s outstanding stock.
